Results 1 to 10 of about 135,357 (309)

JAK Inhibitor and Crohn’s Disease [PDF]

Biomedicines
Crohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu, Shi Wang, Sanping Xu, Rui Gong   +3 more
doaj   +2 more sources

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study [PDF]

ACR Open Rheumatology
Objective To evaluate the clinical characteristics and serum cytokine profiles of patients with anti‐MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM‐ILD) treated with JAK inhibitors and to compare survivors and ...
Haruna Matsuo, Tomohiro Koga, Toshimasa Shimizu, Hiroyuki Ide, Serina Koto, Kanako Kojima, Yuya Fujita, Momoko Okamoto, Ayuko Takatani, Takahisa Suzuki, Yuta Matsushita, Atsushi Kawakami   +11 more
doaj   +2 more sources

JAK inhibitor: Introduction

Indian Journal of Dermatology, Venereology and Leprology, 2023
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri, Smriti K, Raychaudhuri   +1 more
openaire   +2 more sources

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Allergology International, 2022
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. The knowledge on the pathogenesis of AD is driving the development of new drugs. From the research results, it has been revealed that Th2 cell-mediated immunity,
Chisa Nakashima, Shigeto Yanagihara, Atsushi Otsuka   +2 more
doaj   +1 more source

JAK inhibitors in rheumatology

Immunological Medicine, 2023
Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating
Kunihiro Yamaoka, Kenji Oku
openaire   +3 more sources

JAK inhibitors for asthma

Journal of Allergy and Clinical Immunology, 2021
Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas, Patrick, Donohue, Margaret, Connolly, Michael E, Wechsler   +3 more
openaire   +3 more sources

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj   +1 more source

JAK inhibitors: Ten years after

European Journal of Immunology, 2021
AbstractThe European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of ...
Francesca Romana Spinelli, Françoise Meylan, John J. O'Shea, Massimo Gadina   +3 more
openaire   +4 more sources

Tofacitinib

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical ...
Nilgün Şentürk
doaj   +1 more source

JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors

Inflammation and Regeneration, 2023
Background Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage/bone destruction because of aberrantly activated osteoclasts.
Shinya Yari, Junichi Kikuta, Hotaka Shigyo, Yu Miyamoto, Daisuke Okuzaki, Yuki Furusawa, Masafumi Minoshima, Kazuya Kikuchi, Masaru Ishii   +8 more
doaj   +1 more source